Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-23-011790

Chief Financial Officer gave up 1,392 shares (to pay taxes)

  • Chief Financial Officer acquired 3,825 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Smith Brendan Chief Financial Officer 2023-02-18 Option exercise +3,825 6,464 D
Smith Brendan Chief Financial Officer 2023-02-21 Shares withheld for taxes −1,392 $48.26 $67,178 5,072 D
Derivatives
Smith Brendan Chief Financial Officer 2023-02-18 Option exercise · Restricted Stock Units −3,825 11,475 D
Loading xslF345X03/doc4.xml…